Differential outcome of an antimicrobial stewardship audit and feedback program in two intensive care units: A controlled interrupted time series study

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Taggart, Linda R ^a,b   Leung, Elizabeth ^a   Muller, Matthew P ^a,b   Matukas, Larissa M ^a,b   Daneman, Nick ^b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Anti infective agents; Bacterial infections; Drug resistance, microbial; Drug utilization; Intensive care; Quality improvement

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CLOXACILLIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DECISION MAKING; ESCHERICHIA COLI; FEEDBACK SYSTEM; HOSPITAL READMISSION; HUMAN; INCIDENCE; INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MORTALITY; NEUROSURGERY; PHARMACIST; PHYSICIAN; PSEUDOMONAS AERUGINOSA; TEACHING HOSPITAL; TIME SERIES ANALYSIS; CLOSTRIDIUM INFECTIONS; CRITICAL ILLNESS; DRUG EFFECTS; ECONOMICS; EPIDEMIOLOGY; FEMALE; MIDDLE AGED; PATHOGENICITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; CANADA; CLOSTRIDIUM INFECTIONS; CRITICAL ILLNESS; ESCHERICHIA COLI; FEMALE; HUMANS; INTENSIVE CARE UNITS; INTERRUPTED TIME SERIES ANALYSIS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

EID: 84945974283     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1223-2     Document Type: Article

References (29)

1. CDC: Antibiotic Resistance Threats in the United States, 2013.
2. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009;22(4):352-8.
3. Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America, Society for Healthcare Epidemiology of America: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-77.
4. Chang HT, Krezolek D, Johnson S, Parada JP, Evans CT, Gerding DN. Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect Control Hosp Epidemiol. 2007;28(8):926-31.
5. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47(6):735-43.
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
7. WHO. The evolving threat of antimicrobial resistance: Options for action. 2012.
8. Solomon DH, Van Houten L, Glynn RJ, Baden L, Curtis K, Schrager H, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001;161(15):1897-902.
9. Lesprit P, Landelle C, Brun-Buisson C. Clinical impact of unsolicited post-prescription antibiotic review in surgical and medical wards: a randomized controlled trial. Clin Microbiol Infect. 2013;19(2):E91-7.
10. Kollef MH, Micek ST. Antimicrobial stewardship programs: mandatory for all ICUs. Crit Care. 2012;16(6):179.
11. Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP. Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med. 2013;41(9):2099-107.
12. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Cooperative Antimicrobial Therapy of Septic Shock Database Research Group: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237-48.
13. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011;66(6):1223-30.
14. DiazGranados CA. Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. Am J Infect Control. 2012;40(6):526-9.
15. Katsios CM, Burry L, Nelson S, Jivraj T, Lapinsky SE, Wax RS, et al. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit Care. 2012;16(6):R216.
16. Elligsen M, Walker SA, Pinto R, Simor A, Mubareka S, Rachlis A, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp Epidemiol. 2012;33(4):354-61.
17. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
18. Marra AR, de Almeida SM, Correa L, Silva Jr M, Martino MD, Silva CV, et al. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting. Am J Infect Control. 2009;37(3):204-9.
19. Cairns KA, Jenney AW, Abbott IJ, Skinner MJ, Doyle JS, Dooley M, et al. Prescribing trends before and after implementation of an antimicrobial stewardship program. Med J Aust. 2013;198(5):262-6.
20. Palmay L, Walker SA , Leis JA , Taggart LR , Lee C, Daneman N: Antimicrobial Stewardship Programs: A Review of Recent Evaluation Methods and Metrics. Curr Treat Options Infect Dis 2014; 6(2):113-131.
21. Burke JP. Antibiotic resistance--squeezing the balloon? JAMA. 1998;280(14):1270-1.
22. Goldstein RC, Husk G, Jodlowski T, Mildvan D, Perlman DC, Ruhe JJ. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms. Am J Infect Control. 2014;42(5):539-41.
23. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004;38(5):646-8.
24. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration. 2006;73(1):27-33.
25. Elphick HE, Jahnke N. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev. 2014;4:CD002007.
26. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI, Executive summary. Pediatr Pulmonol. 2013;48(6):525-37.
27. Geissler A, Gerbeaux P, Granier I, Blanc P, Facon K, Durand-Gasselin J. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs. Intensive Care Med. 2003;29(1):49-54.
28. De Pestel DD, Eiland 3rd EH, Lusardi K, Destache CJ, Mercier RC, McDaneld PM, et al. Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter. Clin Infect Dis. 2014;59 Suppl 3:S154-61.
29. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44(5):664-70.